11/26
09:31 am
crsp
Rating for CRSP
Low
Report
Rating for CRSP
11/12
04:02 pm
crsp
Rating for CRSP
Medium
Report
Rating for CRSP
11/12
04:02 pm
crsp
Rating for CRSP
Medium
Report
Rating for CRSP
11/11
10:19 am
crsp
Rating for CRSP
Medium
Report
Rating for CRSP
11/11
10:19 am
crsp
Rating for CRSP
Medium
Report
Rating for CRSP
11/11
08:13 am
crsp
Rating for CRSP
Low
Report
Rating for CRSP
11/11
08:13 am
crsp
Rating for CRSP
Low
Report
Rating for CRSP
11/11
07:03 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
11/11
07:03 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
11/11
06:02 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/10
12:04 pm
crsp
Rating for CRSP
Low
Report
Rating for CRSP
11/10
12:04 pm
crsp
Rating for CRSP
Low
Report
Rating for CRSP
10/10
11:17 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $81.00 price target on the stock.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $81.00 price target on the stock.
10/10
11:02 am
crsp
Rating for CRSP
Low
Report
Rating for CRSP
10/10
11:02 am
crsp
Rating for CRSP
Low
Report
Rating for CRSP
9/23
08:07 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
9/18
08:09 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $70.00 price target on the stock.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $70.00 price target on the stock.
9/18
06:54 am
crsp
Rating for CRSP
Low
Report
Rating for CRSP
9/18
04:55 am
crsp
Crispr Therapeutics initiated with an Overweight at JPMorgan
Low
Report
Crispr Therapeutics initiated with an Overweight at JPMorgan